Health Condition 1: H353- Degeneration of macula and posterior pole Health Condition 2: H40- Glaucoma Health Condition 3: E113- Type 2 diabetes mellitus with ophthalmic complications
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Strand Life Sciences Private Limited
Eligibility
Inclusion criteria
Inclusion criteria: 1.Individuals with a confirmed diagnosis of one or more of the above diseases, along with adequate supporting clinical information (age at onset, diagnostic methods, details of disease progression, underlying medical history, phenotypic characteristics and associated SOC test results) 2.Familial cases with access to affected family members is desired 3.Ability to understand the purpose of the study and willingness to sign an Informed Consent Form 4.Willingness to provide 13-23 mL of blood 5.Tear sample (if available and possible) may be collected for DR and AMD cases only 6.Willingness to be contacted in future for recording health updates.
Exclusion criteria
Exclusion criteria: 1.Individuals with chronic uncontrolled infection 2.Individuals with any acute illness or infection 3.Pregnant and lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The outcome of the study will aid in identification of genomic alterations associated with specific phenotypic traits & subtypes yielding novel gene-disease associations which can serve as (i) early detection biomarker (ii) diagnostic/prognostic marker & (iii) novel therapeutic targets.Timepoint: At baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| Not AvailableTimepoint: Not Applicable | — |
Countries
India
Contacts
Public ContactDr Vamsi Veeramachaneni
Strand Life Sciences Private Limited
Outcome results
None listed